— AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.
— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Products sales rose 8% year-over-year to $6.25 billion.
— Oncology sales advanced by 29% and respiratory sales grew by 13%. Biopharmaceuticals sales increased by 10% and new CVRM sales rose by 6% while sales in other medicines fell by 17%.
— Depending on the impact of the novel coronavirus (Covid-19) outbreak, AstraZeneca expects FY20 revenue to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage.
— Guidance assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus (Covid-19) outbreak.
— AZN stock, which advanced 4% in the last three months, was down slightly during the before-market session.
Most Popular
Earnings Preview: Johnson & Johnson bets on innovation to stay in growth mode
Over the years, Johnson & Johnson (NYSE: JNJ) has remained a dominant player in the medical industry, benefitting from its unique business model and growth strategy focused on constant innovation.
Key takeaways from PepsiCo’s Q3 2024 earnings report
Shares of PepsiCo, Inc. (NASDAQ: PEP) gained over 1% on Tuesday even though the company delivered mixed results for the third quarter of 2024 and lowered its guidance for the
PEP Earnings: All you need to know about PepsiCo’s Q3 2024 earnings results
PepsiCo, Inc. (NASDAQ: PEP) reported its third quarter 2024 earnings results today. Net revenue dipped 0.6% to $23.3 billion compared to the same period a year ago. Organic revenue growth
